July 29 (Reuters) - Pcas SA PCAS.PA :
* CONSOLIDATED NET SALES OF EUR 109.8 MILLION AS OF JUNE 30,
2022,
A 3.3% INCREASE
* WILL GENERATE A FURTHER SIGNIFICANT CURRENT OPERATIONAL
LOSS IN
FIRST HALF OF 2022, STILL NEGATIVELY AFFECTED BY BUSINESS LEVELS
THAT ARE STILL NOT SUFFICIENT TO COVER FIXED COSTS INCURRED AT
SEVERAL PHARMACEUTICAL SYNTHESIS SITES, AND INVENTORY
DEPRECIATIONS LINKED TO NON-COMPLIANT PRODUCTIONS
* 2022 HALF-YEAR FINANCIAL STATEMENTS WILL INCLUDE AN
EXPENSE OF
EUR 14.5 MILLION CORRESPONDING TO AN IMPAIRMENT OF GROUP'S
GOODWILL, AS AN IMMEDIATE CONSEQUENCE OF AN INCREASE IN DISCOUNT
RATE USED TO DETERMINE FUTURE OPERATING CASH FLOWS AS PART OF
IMPAIRMENT TESTS
Source text for Eikon: ID:nGNE7zTPkb
Further company coverage: PCAS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))